Monograph Pharma — Global Pharmaceutical Sourcing, CDMO & Licensing Partner

We Care Your Health

A single-point pharmaceutical partner — from India's manufacturing strength to global markets.

Monograph Pharma delivers high-quality medicines across niche and generic segments — backed by integrated sourcing, CDMO, licensing, regulatory, and facility capabilities, and partnerships built on collaboration and integrity.

Backed by our joint venture with Zeino Pharma FZ LLC, Monograph Pharma builds a niche-to-generic pharmaceutical portfolio bringing superior-quality, affordable medicines to patients across the GCC, MENA, Africa, CIS, Southeast Asia, Asia Pacific, and Latin America.

Strategic Joint Venture

Zeino Pharma logo

Zeino Pharma, UAE

0+
Products in Portfolio
0+
Manufacturing partners
0+
Countries served
SRA & WHO-GMP Network
US FDA, EU-GMP & PIC/S audited
CTD / eCTD Dossiers
Submission-ready documentation
Single-Point Accountability
Techno-commercial & supply execution
Global Supply Reliability
GCC, MENA, Africa, CIS, APAC, LATAM

Our Products

Loading catalogue…

Loading product catalogue

Global Presence

Strategic reach across regulated, semi-regulated, and emerging markets

3D Political Globe· Drag to rotate • Hover country borders
MPPL (HQ)Zeino (JV)
India (HQ)— Global Headquarters • Drag to rotate
Political View

Our Clients

We are proud to have worked with a diverse range of clients across various industries. Here are some of the organizations we have had the privilege to serve.

What Our Partners Say

Real feedback from the manufacturers and partners we work with

Corporate Knowledge Base & AEO Guide

Frequently Asked Questions

Authoritative, answer-first insights into our international pharmaceutical sourcing, CDMO processes, EU/WHO-GMP compliance, and joint venture infrastructure.

DIRECT ANSWER

Monograph Pharma is an integrated pharmaceutical sourcing, CDMO, and consultancy partner headquartered in Hyderabad, India. In joint venture with Zeino Pharma UAE, the company delivers end-to-end solutions across global pharmaceutical sourcing, contract development and manufacturing (CDMO), CTD/eCTD dossier licensing, regulatory compliance consulting, and turnkey cleanroom facility engineering for international markets.

Key Strategic Highlights
Global Sourcing: Finished dosage formulations, active pharmaceutical ingredients (APIs), and pellets
CDMO Facilitation: Tech transfer, pilot formulation, and commercial-scale cGMP manufacturing
Dossier Licensing: In-licensing and out-licensing of submission-ready CTD and eCTD files
Regulatory Consulting: MOH approvals, audit readiness, and compliance strategy for emerging markets
Facility Engineering: Cleanroom planning, HVAC cascading, and qualification to EU-GMP standards

DIRECT ANSWER

Monograph Pharma manages contract development and manufacturing (CDMO) projects with single-point accountability. The process encompasses pre-formulation screening, analytical method development, pilot batch scale-up, ICH-compliant stability testing, technology transfer, and commercial-scale batch manufacturing, helping brand owners bring high-quality generic and novel formulations to market with reduced lead times and capital efficiency.

Key Strategic Highlights
Formulation Development: Lab-scale prototyping, excipient compatibility, and dissolution profiling
Pilot & Scale-Up: Validation batches with established Critical Process Parameters (CPPs)
Regulatory Documentation: Preparation of Module 3 Quality/CMC documentation for dossier filing
Commercial Production: Flexible batch sizing from clinical trial quantities to multi-million unit commercial runs
Continuous Quality Assurance: In-process controls and post-marketing stability commitment

DIRECT ANSWER

All pharmaceutical formulations supplied by Monograph Pharma are manufactured exclusively in audited facilities compliant with cGMP standards. Partner manufacturing suites hold active WHO-GMP certifications, with key facility lines audited by Stringent Regulatory Authorities (SRAs) including the US FDA, EU-GMP, PIC/S, and regional health ministries, ensuring rigorous analytical testing, stability data, and batch documentation.

Key Strategic Highlights
Stringent Regulatory Authorities (SRA): Facilities approved by or built to US FDA, EU-GMP, and PIC/S standards
WHO-GMP Certified: Active certification across all partner manufacturing lines in India
Comprehensive Testing: Dual release testing, Certificate of Analysis (COA), and Batch Manufacturing Records (BMR)
Climatic Zone Stability: Long-term and accelerated stability data covering Zone IVa and Zone IVb conditions
Complete Traceability: Barcoded batch packaging and tamper-evident serialization across all shipments

DIRECT ANSWER

Monograph Pharma provides submission-ready Common Technical Document (CTD) and electronic CTD (eCTD) dossiers spanning Modules 1 through 5, supported by complete bioequivalence (BE) studies, analytical method validations, and Zone IVb stability data. Our regulatory affairs team assists client partners through regional health authority submissions, query responses, and Marketing Authorization (MA) transfers across the GCC, MENA, CIS, and emerging markets.

Key Strategic Highlights
Format Compliance: Complete Modules 1–5 in standardized CTD and regional eCTD electronic formats
Bioequivalence Backing: In-vivo and in-vitro bioequivalence data from audited CRO partner centers
Health Authority Support: Active guidance answering regulatory queries from MOH, SFDA, and regional bodies
Dossier In-Licensing: Ready dossiers available for immediate regional filing and commercial out-licensing

DIRECT ANSWER

Monograph Pharma provides a diversified portfolio of over 300 pharmaceutical products across generic and specialty segments. The catalogue spans oral solids (tablets, capsules, orally disintegrating tablets), modified-release pellets and granules, sterile parenterals, lyophilized injectables, oral liquids, topical semi-solids, and specialized nutraceutical formulations manufactured in strict compliance with international pharmacopeias.

Key Strategic Highlights
Antibiotics & Anti-Infectives: Cephalosporins, Beta-lactams, Fluoroquinolones, Carbapenems
Pellets & Granules: Enteric-coated, sustained-release, and modified-release pellet formulations
Chronic Care: Cardiovascular, anti-diabetic, anti-hypertensive, and lipid-lowering therapies
Central Nervous System (CNS): Neuropsychiatry, analgesics, anticonvulsants, and pain management
Hospital Specialty: Oncology, critical care parenterals, and supportive therapy injectables
Nutraceuticals: Premium dietary supplements, botanical extracts, and effervescent dosage forms

DIRECT ANSWER

Yes. Monograph Pharma delivers complete private labeling and bespoke packaging solutions tailored to client brand guidelines and regional language requirements. All commercial packaging lines feature 2D DataMatrix track-and-trace serialization, GS1 barcodes, and tamper-evident closures in compliance with international anti-counterfeiting regulations and national track-and-trace systems.

Key Strategic Highlights
Bilingual Packaging: Arabic/English, French/English, and regional language artwork adaptation
GS1 Serialization: 2D DataMatrix barcodes compliant with SFDA Tatmeen, UAE Tatmeen, and international mandates
Custom Primary Packaging: Alu-Alu blisters, PVC/PVDC, child-resistant push-through packs, and amber glass vials
Tamper Evidence: Integrated tamper-evident seals and security holograms for brand protection

DIRECT ANSWER

Monograph Pharma operates in a formal strategic joint venture with Zeino Pharma FZ LLC, an established scientific center and Marketing Authorization Holder (MAH) located in Dubai Science Park, UAE. This cross-border alliance combines India's formulation development speed and SRA/WHO-GMP manufacturing strength with Zeino Pharma's commercial presence and direct regulatory access across the GCC and MENA regions.

Key Strategic Highlights
Single-Point Solution: One unified partner managing sourcing in India and market distribution in the GCC/MENA
Regulatory Advantage: Direct Marketing Authorization Holder (MAH) capabilities in Dubai Science Park
Dual Corporate Presence: Headquarters in Hyderabad, India and regional partner office in Dubai, UAE
Verified Compliance: Audited manufacturing network meeting international health authority standards

DIRECT ANSWER

International distributors, ministries of health, hospital procurement agencies, and private brand owners can partner with Monograph Pharma by submitting commercial inquiries directly through our online portal or via email at bd@monographpharma.com. Our business development team provides techno-commercial evaluations, dossier reviews, sample shipments, and supply agreements within 1–2 business days.

Key Strategic Highlights
Rapid Turnaround: Techno-commercial proposals and product specifications shared within 24–48 hours
Dossier Evaluation: Fast-track review of CTD/eCTD dossier availability for regional registration
Sample & COA Dispatch: Regulated dispatch of evaluation samples with verified testing documentation
Flexible Commercial Terms: Tailored contract packaging, private labeling, and regional exclusivity agreements
Multi-Market Support: Active logistics servicing GCC, MENA, Africa, CIS, Southeast Asia, and Latin America
Techno-Commercial Support

Have a Specific Regulatory, Sourcing, or Dossier Requirement?

Our business development and regulatory affairs desk provides custom feasibility assessments, dossier reviews, and techno-commercial proposals within 1–2 business days.

Contact Us

Connect with our global business development and regulatory team for sourcing, licensing, CDMO, and distribution partnerships.

Monograph Pharma · India (HQ)
Address
3rd Floor, 91Springboard -71, Hitech, Jubilee Enclave Road, HITEC City, Hyderabad, Telangana 500081, India
Zeino Pharma — Dubai, UAE · JV Partner
Address
Office 703, 7th Floor, North Tower, HQ Building, Dubai Science Park, Dubai, UAE. P.O. Box: 478861
General Inquiries
info@zeinopharma.com
Fax
+971 4 368 4806

Send Us a Message